Amary, F;
Pillay, N;
Flanagan, AM;
(2017)
Molecular testing of sarcomas.
Diagnostic Histopathology
, 23
(10)
pp. 431-441.
10.1016/j.mpdhp.2017.08.003.
Preview |
Text
Flanagan_AMF K36 Antibody Chondroblastoma R2 21_1_16.pdf - Accepted Version Download (444kB) | Preview |
Abstract
Connective tissue tumours, particularly sarcomas, are rare and present as a variety of histological subtypes with diverse management protocols and have varied prognoses. Many of these tumours have specific cancer driver genetic alterations that can be leveraged for diagnostic purposes. For practical purposes, these tumours can be categorised as harbouring genetic alterations including chromosomal rearrangements, gene amplifications, single nucleotide substitutions, and complex genetic abnormalities. Herein we discuss different tumour subtypes with their associated genetic abnormalities that may be used in clinical practice, when interpreted in the context of the relevant clinical, histological and radiological information. The benefits of large scale sequencing studies of sarcoma are leading to new insights into sarcoma development and are providing a biological rationale for personalised medicine. Genomic profiling and other “omic” studies will likely play a fundamental part in the development of new diagnostic and predictive biomarkers in the near future.
Archive Staff Only
 |
View Item |
